Cyclophosphamide-Cisplatin Versus Cyclophosphamide-Carboplatin in Stage III-IV Ovarian Carcinoma: A Comparison of Equally Myelosuppressive Regimens

For several years investigators involved in the therapy of ovarian carcinoma have been interested in the possibility that cisplatin (CDDP) might be replaced by carboplatin (CBDCA) in combination drug regimens because of the better gastrointestinal tolerance for CBDCA and because of its lesser risks of renal and neural toxic effects. That possibility formed the basis for the comparative study described below